Search

The article discusses patient preferences for intervention in the setting of precursor multiple myeloma, focusing on the challenges of managing monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). The study used a conjoint analysis instrument to assess patient preferences regarding intervention attributes, such as MM prevention, cost, inconvenience, and side effects. Findings revealed a strong preference for interventions with a higher likelihood of preventing MM and low side effect profiles, highlighting the need for diverse treatment options to meet the preferences of this unique patient population. The study was funded by various organizations and involved multiple authors who contributed to the research. [Extracted from the article]

This article explores patient preferences for intervention in precursor multiple myeloma (MM) and presents a conjoint analysis survey that assesses these preferences. The survey found that patients prioritize interventions that have a higher likelihood of preventing MM and avoiding side effects. The study also identified three profiles of patients based on their attribute preferences: those who prioritize avoiding side effects, those who prioritize low cost, and those who prioritize preventing myeloma. The study acknowledges limitations but suggests that a range of interventions will be needed to meet the preferences of patients with precursor diseases. [Extracted from the article]

The original article can be found online at https://doi.org/10.1038/s41408-024-01161-0.Correction to: Blood Cancer Journalhttps://doi.org/10.1038/s41408-024-01161-0, published online 14 October 2024In this article the author's name Omar Nadeem was incorrectly written as Nadeem Omar.By Catherine R. Marinac; Katelyn Downey; Jacqueline Perry; Brittany Fisher-Longden; Timothy R. Rebbeck; Urvi A. Shah; Elizabeth K. O'Donnell; Irene M. Ghobrial; Omar Nadeem and Brian L. EglestonReported by Author; Author; Author; Author; Author; Author; Author; Author; Author; Author [Extracted from the article]

We aimed to improve the understanding of genotype–phenotype correlations in Rett syndrome (RS) by adopting a novel approach to categorising phenotypic dimensions – separating typicality of presentation, outcome severity and age of onset – and by classifying MECP2 mutations strictly by predicted functional attributes. MECP2 mutation screening results were available on 190 patients with a clinical diagnosis of RS (140 cases with classic RS, 50 with atypical RS). 135 cases had identified mutations. Of the 140 patients, 116 with classic RS (82.9%) had an identified mutation compared with 19 of 50 patients (38%) with an atypical presentation. Cases with early onset of regression and seizures, and those with clinical features that might indicate alternative aetiologies, were less likely to have mutations. Individuals with late truncating mutations had a less typical presentation than cases with missense and early truncating mutations, presumably reflecting greater residual function of MECP2 protein. Individuals with early truncating mutations had a more severe outcome than cases with missense and late truncating mutations. These findings held when restricting the analysis to cases over 15 years of age and classic cases only. Previous findings of variation in severity among the common mutations were confirmed. The approach to phenotypic and genotypic classification adopted here allowed us to identify genotype–phenotype associations in RS that may aid our understanding of pathogenesis and also contribute to clinical knowledge on the impact of different types of mutations.European Journal of Human Genetics (2005) 13, 1121–1130. doi:10.1038/sj.ejhg.5201471; published online 3 August 2005 [ABSTRACT FROM AUTHOR]

Recent studies have reported the presence of simian virus 40 (SV40) DNA sequences in approximately 40% of tumor samples from non-Hodgkin's lymphoma (NHL) patients from the United States. We examined a series of 259 tumor and blood samples, including 152 NHL samples, from patients in the U.K. with lymphadenopathy and lymphoid leukemia for the presence of SV40 DNA using a highly sensitive quantitative polymerase chain reaction (PCR) assay and a consensus PCR assay capable of detecting the polyomaviruses SV40, BK, and JC. SV40 DNA sequences were not detected in any sample using either assay. Because the incidence of NHL is similar in the U.K. and the United States, this finding suggests that SV40 is unlikely to have an etiologic role in NHL. [ABSTRACT FROM AUTHOR]

Copyright of Stimulus is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Stimulus is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

The author comments on an article by Dr. Mumford wherein he has provided information about medicolegal work to aspiring medicolegal experts. She mentions that Dr. Mumford has covered all main problems and pitfalls encountered when a doctor is instructed as an expert, and had given clear guidance on how to face a judge or a counsel. The author states that as a counsel, she would advice experts who are to appear before a court to ask for guidance on procedure or content from their counsel.